Logo image of VTYX

VENTYX BIOSCIENCES INC (VTYX) Stock Fundamental Analysis

USA - NASDAQ:VTYX - US92332V1070 - Common Stock

2.98 USD
+0.29 (+10.78%)
Last: 9/26/2025, 8:00:02 PM
2.98 USD
0 (0%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

2

Overall VTYX gets a fundamental rating of 2 out of 10. We evaluated VTYX against 196 industry peers in the Pharmaceuticals industry. While VTYX has a great health rating, there are worries on its profitability. VTYX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VTYX has reported negative net income.
VTYX had a negative operating cash flow in the past year.
In the past 5 years VTYX always reported negative net income.
In the past 5 years VTYX always reported negative operating cash flow.
VTYX Yearly Net Income VS EBIT VS OCF VS FCFVTYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VTYX has a worse Return On Assets (-51.75%) than 60.71% of its industry peers.
VTYX has a Return On Equity (-56.85%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.75%
ROE -56.85%
ROIC N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTYX Yearly ROA, ROE, ROICVTYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VTYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTYX Yearly Profit, Operating, Gross MarginsVTYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for VTYX has been increased compared to 1 year ago.
Compared to 5 years ago, VTYX has more shares outstanding
VTYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTYX Yearly Shares OutstandingVTYX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VTYX Yearly Total Debt VS Total AssetsVTYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 1.69, we must say that VTYX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.69, VTYX is in the better half of the industry, outperforming 63.27% of the companies in the same industry.
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACCN/A
VTYX Yearly LT Debt VS Equity VS FCFVTYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 19.12 indicates that VTYX has no problem at all paying its short term obligations.
VTYX has a better Current ratio (19.12) than 89.80% of its industry peers.
VTYX has a Quick Ratio of 19.12. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VTYX (19.12) is better than 89.80% of its industry peers.
Industry RankSector Rank
Current Ratio 19.12
Quick Ratio 19.12
VTYX Yearly Current Assets VS Current LiabilitesVTYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

VTYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.57%, which is quite impressive.
EPS 1Y (TTM)39.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VTYX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.68%
EPS Next 2Y0.54%
EPS Next 3Y0.6%
EPS Next 5Y14.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VTYX Yearly Revenue VS EstimatesVTYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
VTYX Yearly EPS VS EstimatesVTYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VTYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTYX Price Earnings VS Forward Price EarningsVTYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTYX Per share dataVTYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.54%
EPS Next 3Y0.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTYX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (9/26/2025, 8:00:02 PM)

After market: 2.98 0 (0%)

2.98

+0.29 (+10.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners68.54%
Inst Owner Change2.32%
Ins Owners4.11%
Ins Owner Change0.02%
Market Cap212.50M
Analysts81.43
Price Target11.22 (276.51%)
Short Float %6.59%
Short Ratio5.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.89%
Min EPS beat(2)20.73%
Max EPS beat(2)21.05%
EPS beat(4)4
Avg EPS beat(4)18.2%
Min EPS beat(4)5.28%
Max EPS beat(4)25.73%
EPS beat(8)7
Avg EPS beat(8)15.19%
EPS beat(12)8
Avg EPS beat(12)5.4%
EPS beat(16)11
Avg EPS beat(16)-37.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.33%
EPS NQ rev (1m)0.63%
EPS NQ rev (3m)9.94%
EPS NY rev (1m)0.51%
EPS NY rev (3m)9.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS2.94
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.75%
ROE -56.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.12
Quick Ratio 19.12
Altman-Z 1.69
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)101.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.56%
EPS Next Y13.68%
EPS Next 2Y0.54%
EPS Next 3Y0.6%
EPS Next 5Y14.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.18%
EBIT Next 3Y9.01%
EBIT Next 5YN/A
FCF growth 1Y30.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.2%
OCF growth 3YN/A
OCF growth 5YN/A